United States Viral Vector and Plasmid DNA Manufacturing Market Analysis | Market Expansion Till 2031 - Cobra Biologics, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies

WILMINGTON, DE, UNITED STATES: Global Viral Vector and Plasmid DNA Manufacturing Market size was valued USD 2.85 billion in 2021 and is estimated to reach USD billion by 2031, growing at a CAGR of 14.2% during the forecast period 2024-2031.

United States Viral Vector & Plasmid DNA Manufacturing Market size in 2024: USD 2.45 B and Projection to reach USD 9.29 B by 2033 with a CAGR: 15.97% (2024-2033)

According to DataM Intelligence has published a new research report on "Viral Vector and Plasmid DNA Manufacturing Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

United States: Recent Industry Developments
✅ October 2025: Thermo Fisher Scientific expanded its plasmid DNA manufacturing capacity to meet growing demand for gene therapies.
✅ September 2025: Merck KGaA launched new viral vector production platforms enhancing scalability and product consistency.
✅ August 2025: Cobra Biologics partnered with biotech firms to accelerate viral vector manufacturing for CAR-T therapies.

Japan: Recent Industry Developments
✅ October 2025: Fujifilm Diosynth Biotechnologies invested in cutting-edge plasmid DNA manufacturing facilities in Japan.
✅ September 2025: Cell and Gene Therapy Catapult collaborated with Japanese research institutes to optimize viral vector production processes.
✅ August 2025: SIRION Biotech advanced manufacturing technologies targeting safer and more efficient gene delivery vectors.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/viral-vector-and-plasmid-dna-manufacturing-market?kb

Latest M&A Activity

Sartorius' 2023 acquisition of Polyplus, a viral vector and plasmid DNA production specialist, continues influencing the market, enhancing integrated manufacturing capabilities for gene and cell therapies.​

Private equity played a pivotal role with investments in companies like PlasmidFactory to expand plasmid DNA capacity, incorporating AI-driven analytics and proprietary purification technologies to improve manufacturing efficiency and consistency.​

Addgene formed a strategic partnership with Promega in July 2025, launching the Promega Plasmid Collection to provide researchers expanded access to high-value plasmid DNA for target engagement and protein interaction studies.​

AGC Biologics launched a dedicated Cell and Gene Technologies Division in November 2025, elevating its manufacturing support for developers needing plasmid and viral vector production capacity

Top Industry Players:

✅ Brammer Bio: Recognized in market reports as one of the established CDMOs in viral vector manufacturing, contributing to capacity expansion especially in the plasmid/Viral‐vector space.

✅ Cobra Biologics: A niche specialist in plasmid DNA and viral vector manufacturing; featured among mid-tier but important players in competitive landscapes.

✅ Cell and Gene Therapy Catapult: Has its own viral vector manufacturing lab (UK) and is identified as one of 30 organizations with commercial-scale vector production capability.

✅ FinVector Vision Therapies: Listed among the limited number of companies capable of both plasmid and vector manufacturing-increasing its relevance as demand grows.

✅ Fujifilm Diosynth Biotechnologies: Emerging as a strong CDMO in the space, with estimates putting its share in the cell & gene therapy manufacturing market at 6-9%.

✅ SIRION Biotech: Named in several market‐reports among key small-to-mid players in the viral vector and plasmid DNA manufacturing market.

✅ UniQure NV: Mentioned in market‐reports as a "key company" in viral vector / plasmid manufacturing, underlining its dual role as a therapy developer + manufacturer.

Latest FDA Approvals and Clinical Trials

FDA approvals continue for gene therapies relying on viral vectors and plasmid DNA, with recent examples including multiple advanced therapies approved in 2024 such as Libmeldy for metachromatic leukodystrophy and BEQVEZTM for hemophilia B.​

Over 500 gene therapies are currently in development globally, with more than 50% utilizing viral vectors like adeno-associated virus (AAV) or lentivirus, underscoring sustained clinical effort and rising demand for GMP-grade vectors.​

Clinical trials are advancing plasmid DNA vaccines and therapeutics for infectious diseases and rare genetic disorders, reflecting growing interest in DNA-based therapies

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=viral-vector-and-plasmid-dna-manufacturing-market?kb

Key Segments:

By Product Type: (Plasmid DNA, Viral Vector, Non-Viral Vector)

By Application: (Cancer, Genetic Disorder, Infectious diseases, Other Diseases)

Regional Analysis for Market:

✅ North America - 42% share (largest market, driven by advanced biopharma and strong R&D infrastructure)

✅ Europe - 30% share (significant presence due to strong biotech hubs and regulatory support)

✅ Asia Pacific - 23% share (fastest-growing region with increasing biopharma investments and contract manufacturing expansion)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/viral-vector-and-plasmid-dna-manufacturing-market?kb

Recent Product Launches and Manufacturing Developments

ProBio CDMO opened a 128,000-square-foot GMP manufacturing facility in New Jersey, supporting clinical-grade plasmid DNA production with rapid turnaround from cell bank to batch release (3 months) and plans to add GMP AAV and lentiviral vector manufacturing by early 2026.​

Catalent and other CDMOs have launched platforms enhancing viral vector manufacturing efficiency and scalability, including RNA-based plasmid production and fill-finish services to meet rising demand for gene therapies and vaccines.​

Technology advancements include process improvements with AI and novel fermentation strains to increase plasmid yield and purity, driving competitive differentiation among contract manufacturers.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/viral-vector-and-plasmid-dna-manufacturing-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.